Abstract: Aryl-substituted naphthyridines and pyridopyrazines are disclosed which are useful in treating allergic reactions, inflammation, peptic ulcers and/or hyperproliferative skin disease. Pharmaceutical compositions and methods of treatment employing such compounds are also disclosed.

Abstract: Novel compounds and compositions which inhibit SRS-A in mammals are disclosed. Methods for preparing said compounds and compositions and methods for their use for treating allergic reactions, inflammation and for reducing the severity of myocardial infarction resulting from heart attack are disclosed.Useful intermediates for preparing said compounds are also disclosed.

Abstract: A trifluoroacetylthio- or trifluoroacetylthioalkyl-substituted divinyl benzene co-styrene polymer and a method for using such polymer are disclosed.

Abstract: A buccal formulation for administering a medicament includes about 1-20% by weight of a soluble, pharmaceutically acceptable adhesive, about 1-10% by weight of a pharmaceutically acceptable disintegrant and a soluble, directly compressible tablet excipient.

Abstract: A process is disclosed for purifying gamma interferon from various contaminants resulting from disruption of the cell in which the interferon was produced. The process provides for sequential removal of (a) nucleic acids, (b) negatively charged contaminating proteins, (c) positively charged contaminating proteins and (d) low and high molecular weight impurities.

Abstract: A method of treating hyperproliferative skin disease with substituted quinoline, [1,5]- and [1,8]- naphthyridine and pyrido[2,3-b]pyrazine derivatives is disclosed. The compounds are also anti-allergic, anti-inflammatory and cytoprotective agents. Methods for their preparation and use are disclosed.

Abstract: A process for the preparation of piperidylidene-dihydro-dibenzo[a,d]cycloheptene or aza-derivatives thereof and intermediates in such process are disclosed.

Abstract: Certain pyrimidine derivatives are useful in treating allergic, inflammatory and hyperproliferative skin diseases and in suppressing the immune response. Methods for preparing the compounds and methods for their use are also described.

Abstract: A device for iontophoretic delivery of active ingredient to a patient, that includes an electrode, a first cavity for holding a solution of at least partially active ingredient in ionizing form to be delivered to a patient, a member for maintaining a solution in the first cavity while allowing passage of active ingredient from the first cavity, and an ion exchange member separating the electrode and the first cavity for inhibiting the flow of ions having a charge similar to the charge of the ionized form of the active ingredient from the electrode means to the first cavity is disclosed. A method for iontophoretic delivery of active ingredients to a patient is also disclosed.

Abstract: This invention relates to organic acid-substituted guanidine compounds. Also disclosed are methods for preparing the compounds, compositions containing them, and methods for their use as anthelmintics.

Abstract: A method for inhibiting the action of enkephalinases in a mammal to thereby elicit an analgesic effect in said mammal is described.Novel compound and compositions useful for accomplishing the method of the invention are also described.

Abstract: Sustained release dosage forms are made of saponified starch-acrylonitrile graft copolymers and an active ingredient.

Abstract: A minipellet dosage form of prednisone or prednisolone, resistant to attack by saliva but readily dissolvable in gastric juice, which comprises a mixture of prednisone or prednisolone and polyvinylpyrrolidone coated onto a nonpareil seed, and further coated with a layer of dimethylaminoethyl and methyl methacrylate copolymer.

Abstract: This invention relates to organic acid-substituted guanidine compounds. Also disclosed are methods for preparing the compounds, compositions containing them, and methods for their use as anthelmintics.

Abstract: A method for the topical treatment of hyperproliferative skin diseases in a human is described.Compounds and compositions for use in this method are also described.

Abstract: Controlled release solid dosage forms comprising less than about one-third of the total dosage form weight of hydroxypropylmethylcellulose USP 2910 are disclosed.

Abstract: Bronchospastic diseases characterized by airway hyperreactivity are treated by administration of the calcium channel blocker gallopamil. Unlike other calcium channel blockers, the effective dose of gallopamil is small enough that undesirable side effects are not present.

Abstract: A method and composition for suppressing the immune response are disclosed which employ an immunosuppressing effective amount of certain tricyclic naphthyridine or pyrido-pyrazine derivatives.

Abstract: Zwitterionic bicyclic compounds are disclosed which are useful as anti-allergic, anti-inflammatory and/or cytoprotective agents. Pharmaceutical compositions and methods of treatment employing such compounds are also disclosed.